Analysts Expect iTeos Therapeutics, Inc. (NASDAQ:ITOS) to Post $4.95 EPS

Wall Street brokerages forecast that iTeos Therapeutics, Inc. (NASDAQ:ITOS) will report earnings per share (EPS) of $4.95 for the current fiscal quarter, according to Zacks. Two analysts have made estimates for iTeos Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.84) and the highest estimate coming in at $14.41. iTeos Therapeutics reported earnings of ($0.48) per share during the same quarter last year, which would suggest a positive year over year growth rate of 1,131.3%. The firm is scheduled to issue its next earnings report on Thursday, November 11th.

According to Zacks, analysts expect that iTeos Therapeutics will report full year earnings of $3.22 per share for the current financial year, with EPS estimates ranging from ($3.09) to $12.87. For the next financial year, analysts expect that the business will report earnings of ($3.12) per share, with EPS estimates ranging from ($4.96) to ($0.77). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for iTeos Therapeutics.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings data on Thursday, August 12th. The company reported ($0.75) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.34).

A number of equities research analysts have commented on the company. SVB Leerink reduced their target price on iTeos Therapeutics from $56.00 to $55.00 and set an “outperform” rating on the stock in a research report on Friday, August 13th. Zacks Investment Research upgraded iTeos Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, August 30th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $47.25.

In related news, major shareholder Bioventures 2018 L.P. Mpm sold 14,294 shares of the business’s stock in a transaction on Wednesday, September 22nd. The stock was sold at an average price of $27.54, for a total value of $393,656.76. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Ansbert Gadicke sold 50,996 shares of the business’s stock in a transaction on Tuesday, September 7th. The shares were sold at an average price of $29.18, for a total value of $1,488,063.28. The disclosure for this sale can be found here. Insiders sold 260,822 shares of company stock worth $7,405,358 in the last 90 days. Company insiders own 3.95% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Lindbrook Capital LLC acquired a new position in iTeos Therapeutics during the 2nd quarter worth $26,000. E Fund Management Co. Ltd. acquired a new position in iTeos Therapeutics during the 1st quarter worth $38,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in iTeos Therapeutics during the 1st quarter worth $56,000. Royal Bank of Canada grew its stake in iTeos Therapeutics by 532.1% during the 1st quarter. Royal Bank of Canada now owns 1,732 shares of the company’s stock worth $59,000 after purchasing an additional 1,458 shares in the last quarter. Finally, FORA Capital LLC acquired a new position in iTeos Therapeutics during the 2nd quarter worth $96,000. 83.69% of the stock is owned by hedge funds and other institutional investors.

NASDAQ ITOS opened at $27.46 on Wednesday. The stock’s fifty day moving average is $26.41 and its two-hundred day moving average is $26.29. The firm has a market capitalization of $966.87 million, a P/E ratio of -13.40 and a beta of 2.43. iTeos Therapeutics has a fifty-two week low of $17.43 and a fifty-two week high of $47.61.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

See Also: What is a Reverse Stock Split?

Get a free copy of the Zacks research report on iTeos Therapeutics (ITOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for iTeos Therapeutics (NASDAQ:ITOS)

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.